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CHAPTER l. GENERAL INTRODUCTION 
Thesis Organization 
This thesis is presented in alternate format and contains two journal papers. The first 
paper is titled "Development of an in vitro model for the study of the response of equine 
tendon fibroblasts to injury and medication." The second paper is titled "The effect of 
polysulfated glycosaminoglycan on production of proteoglycan by equine tendon fibroblasts in 
monolayer culture." Each paper contains its own summary, introduction, materials and 
methods, results, discussion and references. The Literature Review is designed as a review of 
the literature that created the ideas to pursue these projects . Additional info rmation on 
specific materials and methods and related results not described in either paper have been 
included in Appendix A. Additional electron micrographs not in the papers have been 
included in Appendix B. 
Introduction 
Tendinitis is a common condition affecting all disciplines of equine athletes (17,25,33). 
Tendinitis of the superficial digital fl exor (SDF) tendon is commonly referred to as "bowed 
tendon" and is characterized by fiber disruption and inflammation within the tendon. Recent 
advances in the diagnosis and treatment of tendinitis have improved the prognosis for this type 
of injury; however, the pathophysiology of degenerative tendon injuries is incompletely 
understood. Investigations into the etiology, prevention, management, early detection and 
treatment of tendinitis are ongoing and will continue to advance the state of the art in this 
area. 
The SDF tendon is of special interest because of its high frequency of injury. 
Thoroughbred racehorses have a particularly high incidence of SDF tendiniti s, especially of 
the forelimbs. Injuries to the SDF tendon account for an estimated 8% to 30% of all racing 
injuries (20,25,46,47) . Mechanical overstretching or repeated microstrains from racing at 
high speeds are the primary causes of flexor tendon injuries . The degree of disruption of the 
tendon fibers varies from mild stretching to complete avulsion and tearing. With the increased 
availability of diagnostic ultrasound, the evaluation, documentation and reassessment of 
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tendon injuries has become routine in veterinary medicine ( 18,20). Ultrasonographic 
examination of tendon injuries provides valuable information about the type and degree of 
tendon damage in an individual case (20). Ultrasound evaluation of injured tendons has 
provided new insights into the pathophysiology of tendinitis (20) . Despite these 
improvements in the early detection and serial evaluation of damaged tendons, a consistently 
successful treatment regimen has yet to be developed. 
Anatomy 
Tendons are the collagenous continuation of an associated muscle and form the 
mechanism of attachment of the muscle to the bone at both the origin and insertion of the 
muscle. There are three main structures that support the metacarpo/metatarsophalangeal 
joints of the horse: the deep and superficial digital flexor tendons and their associated check 
ligaments and the suspensory ligament. These support structures are able to sustain high 
loads and strains during the course of normal daily exercise. Jn vitro studies have 
demonstrated that strains of approximately 3% result in reversible, elastic lengthening of the 
tendon (25,36). As strains increase, the tendon behavior becomes viscoelastic until failure 
occurs at strains between 8% and 20% (13,25,55). The strains that have been measured in the 
SDF tendon of galloping Thoroughbreds, around 16%, is very close to the yield and failure 
strains measured in vitro (25,49). 
Tendon is a dense regular connective tissue composed of an extracelluar matrix of four 
main macromolecules: collagen, elastin, proteoglycans and connective tissue glycoproteins. 
The extracelluar matrix is produced and maintained by tendon cells that are present in low 
numbers within the matrix. The tenocytes are arranged in rows between the collagen bundles. 
Three types of tenocytes have been described, but not thoroughly characterized: ( 1) cells with 
flattened cigar shaped dense nuclei, (2) cells located in linear groupings with more rounded 
dense nuclei and (3) immature cells with less dense open nuclei (25) . 
The collagen fibers and ground substance are arranged in a complex manner that is 
visible on both a macroscopic and a microscopic level. The collagen fibers are densely 
packed, arranged in parallel and embedded in ground substance or proteoglycans. In a mature 
animal, tendon fibers demonstrate a larger diameter and an increase in the number of 
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non-reducible collagen cross-links (25). This arrangement of collagen fibers is what creates 
the high tensile strength of tendon. Collagen comprises approximately 80% to 90% of the dry 
weight of tendon (25,38). In normal adult equine tendon, type I collagen fibers predominate 
( 10). A small portion of type III and V fibers are also present associated with basement 
membranes and the intra tendinous vasculature ( 10). 
The endotenon is a thin sheet of loose connective tissue which serves to arrange the 
collagen fibers into bundles or fascicles in a hierarchical manner. The endotenon carries blood 
vessels, lymphatics and nerves into the body of the tendon. It arises from the epitenon, a 
thicker connective tissue layer which surrounds the entire tendon (38,41). In the straight 
areas of the limbs where the tendon is not surrounded by a tendon sheath, the tendon is 
enclosed in a layer of vascular connective tissue. This outer layer is known as the paratenon 
and allows the tendon to move beneath the skin ( 41 ) . Specialized types of fibroblasts are 
located within the extracellular matrix of the paratenon, epitenon and endotenon and lend each 
its unique function (10) . Tendon healing occurs via both intrinsic and extrinsic mechanisms 
(2,34,48,55). The populations of fibroblasts within the connective tissue framework as well as 
those within the tissue parenchyma are capable of responding to tendon injury and initiating 
tissue repair (19,32,34). 
Proteoglycans form a small but vital percentage of the dry weight of tendon (up to 
5%) (3) . Proteoglycans are complex macromolecules formed by the addition of one or more 
glycosarninoglycan (GAG) side chains to a protein core. These side chains are polymers of 
repeating di saccharides. Proteoglycans may assemble around a molecule of hyaluronic acid to 
form giant aggregates responsible for the viscoelastic nature of tendon. They provide 
resilience and flexibility to the connective tissue matrix. Studies in other species of animals 
have shown that the distribution of individual GAGs appears to be regulated based on the 
tensional forces placed on the tendon (54). In areas of high tension such as the 
mid-metacarpus, the predominant GAG is dermatin sulfate. Where compressional forces 
predominate, chondroitin sulfate is the major GAG. Although these studies have not been 
repeated in the horse, the consistency across species suggests that one could expect to find a 
similar distribution in the horse. 
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Literature Review 
Traditional modes of treatment for tendinitis have included medical and surgical 
therapy ( 4, 12, 15, 18,21,24,26,27,42,56). Treatment is aimed at decreasing inflammation 
within the tendon, preventing further trauma to the damaged tissues, stimulating the healing 
process and preventing recurrence of the injury after the horse goes back into training. 
Whether medical or surgical treatment (or a combination of the two) is selected, enforced rest 
with gradually increasing controlled exercise is the cornerstone of successful treatment 
( 4, 14,29). With traditional modes of therapy, retrospective studies show that approximately 
40% to 60% of injured horses return to athletic soundness following injury to the SDF tendon 
(16,20). 
Collagen turnover in normal tendon is slow (9) . It is estimated that tendon renews all 
its collagen approximately every six months ( 48). The repair and maturation phases of tendon 
healing start at about four days and last for as long as six months (22,48). During this time 
new collagen fibers are produced and realigned along the lines of stress. Type III collagen is 
initially present in increased proportions to Type I collagen compared to normal tendon and 
results in decreased tensile strength of the healing tendon (2 1,57). As the maturation phase of 
wound healing progresses, Type Ill collagen is gradually replaced with Type I collagen 
(22,48) . Up to eight months or more than a year may be required before an athlete is ready to 
return to competition ( 16,22,29,39). In studies following surgical treatment of SDF tendinitis, 
six to 19 months were required to get horses back to racing (16,29). 
Because of the inherently slow healing of tendinous tissues, extended periods of rest 
and rehabilitation are required regardless of the treatment method(s) chosen. Given the 
prolonged rest period and guarded prognosis for return to racing, SDF tendinitis represents a 
significant economic loss to the equine industry. Losses occur in the form of veterinary costs, 
prolonged layup time and training costs incurred during rehabilitation. Recurrent tendinitis or 
severe injury may result in early retirement from athletic function (28,47). 
The focus of research in the field of tendon injuries is aimed at the early detection of 
tendinitis prior to catastrophic fai lure, improving the speed and quality of tendon healing and 
preventing reinjury. Few controlled studies have been performed to objectively evaluate the 
various treatments for tendinitis that have been reported . Recent studies have focused on the 
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prospective evaluation of the most current therapies in order to provide objective data for 
comparison. The long term objective of research in the area of tendon healing is to develop 
methods of modulating tendon healing, minimizing the recovery period and maximizing the 
quality of the healed tissues. 
Modulation of tendon healing through the use of local or systemic medications such as 
polysulfated glycosaminoglycan (PSGAG), hyaJuronic acid, f3-aminoproprionitrile fumarate 
and growth factors is an area of significant research interest (15, 18,21 ,37,42,43,50). Studies 
have traditionally been aimed at evaluation of response on the macroscopic level. The 
specifics of tendon healing on a cellular/biochemicaJ level are incompletely understood. 
Further investigation into the biochemistry and cellular response of normal equine tendon 
fibroblasts is essential in order to gain a further understanding of the pathways stimulated in 
the promotion of tendon healing. 
Tendon cells have been cu ltured in vitro from chickens, rabbits, cattle and humans 
(1 ,8, 11 ,44,51 ,53). Equine tendon explants have been used on a limited basis to investigate the 
response to insulin-like growth factor 1 (3 7) and in a pilot study to optimize tissue culture 
conditions ( 45) . Oxidative energy metabolism and the effects of hypoxia, free radicals and 
hyperthermia have also been investigated using equine tendon fibroblasts cultured in vitro (3). 
These data have yet to be published in a widely distributed form. To the authors' knowledge 
there is not any established model by which the characteristics of equine tendon cells may be 
studied in vitro for application to the clinical problem of SDF tendinitis. 
Polysulfated glycosaminoglycan has been studied extensively for its effects on cartilage 
(5-7,23 ,30,31 ,52,58). Polysulfated glycosaminoglycan is a polymeric chain of repeating units 
of hexosamine and hexuronic acid, highly sulfated glycosaminoglycans. It is structuraJly 
similar to the glycosaminoglycans produced by mesenchymal cells such as tendon fibroblasts . 
It is thought to promote the synthesis of cartilage matrix components and collagen (23). It is 
also a potent inhibitor of the lysosomal hydrolases and neutral metalloproteases that are 
responsible for cartilage matrix and collagen destruction (5,31,35,40). 
The effects of PSGAG on tendon healing have been investigated on a limited basis in 
the horse and the rabbit (25,38,42). Two of these studies used a collagenase induced model 
of SDF tendinitis (38,42) and a third followed the progress of clinical cases of acute tendinitis 
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in horses (25) . Systemic administration of PSGAG significantly improved the rate and quality 
of tendon healing in horses ( 42). Local (intra- and peri-lesiona1) treatment of collagenase 
injury in rabbits decreased swelling, restored tissue organization and alignment and protected 
collagen fibers rrom degeneration (3 8). There was a reduced but measurable effect following 
systemic administration of PSGAG in the rabbit (38) . Clinical trials following local injection 
of PSGAG in the horse have resulted in a rapid reduction of pain and swelling along with 
encouraging overall results (25). The mechanism of action involved in the improved tendon 
healing is uncertain . Controlled studies on a molecular level are limited. The development of 
a reliable cell culture model may help investigate the effects of PSGAG on the biochemical 
products of cultured equine tenocytes. The information gathered via the in vitro studies may 
subsequently be applied to the larger clinical problem of tendinitis. 
The origin for thi s thesis was the need for a better understanding of tendon response 
to injury and to pharmacological manipulations. The development of an in vitro model was 
necessary to study the tendon response on a cellular level. The major objective of this thesis 
was the development of a reliable model for the evaluation of equine tendon fibroblasts in cell 
culture. In addition, the model was used to study the effects of one particular medication, 
polysulfated glycosam.inoglycan (PS GAG), on the production of proteoglycan by the equine 
tendon fibroblasts. 
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CHAPTER 2. DEVELOPMENT OF AN IN VITRO MODEL FOR THE STUDY OF 
THE RESPONSE OF EQUINE TENDON FIBROBLASTS 
TO INJURY AND MEDICATION 
A paper accepted by Veterinary and Comparative Orthopaedics and Traumatology 
Linda A. Dahlgren, Ricardo F. Rosenbusch, Larry C. Booth 
Summary: 
Equine tendon fibroblasts were isolated from explants of superficial digital flexor 
tendon, subcultured and maintained in monolayers. The cells were characterized by light 
microscopy, electron microscopy and radiolabel studies for proteoglycan production. Two 
predominant cell morphologies were identified . The cells dedifferentiated toward a more 
spindle shape with repeated subcultures. Equine tendon fibroblasts were successfully 
cryopreserved and subsequently subcultured. The abi lity to produce proteoglycan was 
preserved. 
The isolated cells were identified as fibroblasts, based on their characteristic shape by 
light microscopy and ultrastructure and the active production of extracellular matrix proteins. 
Abundant rough endoplasmic reticulum and the production of extracellular matrix products 
demonstrated active protein production and export. Proteoglycans were measurable via liquid 
scintillation counting in both the cell-associated fraction and free in the supernatant. This 
model is currently being utilized to study the effects of polysulfated glycosaminoglycan on 
tendon healing. Future uses include studying the effects of other pharmaceuticals, such as 
hyaluronic acid, on tendon healing. 
Introduction: 
Injuries involving the digital flexor tendons are a common cause of lameness in 
performance horses. It is estimated that 7-30% of inju ries incurred by racehorses are related 
to the digital flexor tendons (20,25,40,41) . The superficial digital flexor (SDF) tendons in the 
forelimbs are most commonly affected (32). 
Equine tendon heals slowly and the structure and function of healed tendon is often 
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suboptimal (20,25,35). Extended periods ofrest and rehabilitation are needed, regardless of 
the treatment method chosen ( 4, 13,30). Recurrent tendinitis, or severe injury, may result in 
early retirement from athletic function. Given the prolonged healing time and a guarded 
prognosis for return to previous athletic performance, SDF tendinitis represents a significant 
economic loss to the equine industry . 
A number of treatments for SDF tendinitis have been developed and used 
(4,11,14,17,18,21,24,27,29,30,37). Few, if any, have shown consistently superior results to 
rest alone. New methods of modulating tendon healing, aimed at improving the quality and 
speed of the healing process, continue to be investigated (14, 18,20,21,34,36,37). Local or 
systemic medications such as polysulfated glycosaminoglycan (PSGAG) and hyaluronic acid 
(HA) have been studied in vivo (18,21,36,37,42). The beneficial effect of PSGAG on tendon 
healing reported by Redding is encouraging (37); however, the mechanism of action is 
unknown. Improved understanding of the cellular responses to medications, such as PSGAG, 
will help advance the treatment of tendinitis. 
The responses to injury and treatment have been measured using ultrasound and 
histopathology (11 ,20,21,37); however, tendon healing is incompletely understood at a 
molecular level. Further investigation into the biochemistry and cellular responses of normal 
equine tendon fibroblasts to injury and medication is essential to further understand the 
biology of equine tendon healing. 
Tendon cells have been cultured in vitro from chickens, rabbits, cattle and humans 
(1 ,7,9,38,43 ,44). Equine tendon explants have been used on a limited basis to investigate the 
response to insulin-like growth factor 1 (34) and in a pilot study to optimize tissue culture 
conditions (39) . Oxidative energy metabolism and the effects of hypoxia, free radicals and 
hyperthermia have also been investigated using equine tendon fibroblasts cultured in vitro (3). 
These data have yet to be published in a widely distributed form. To the authors' knowledge 
there is not any established model by which the characteristics of equine tendon cells may be 
studied in vitro for application to the clinical problem of SDF tendinitis. 
Our goal was to develop an in vitro model for investigating the effects of available 
pharmaceuticals on tendon healing at a cellular level. The specific objectives of this study 
were to describe certain morphological and biochemical characteri stics of equine tendon 
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fibroblasts grown in vitro . 
Materials and Methods: 
The middle one thjrd of the SDF tendons were harvested aseptically from the forelimbs 
of nine horses (two to 14 years old) immediately following euthanasia. Horses were 
euthanatized for reasons other than tendiniti s. Evaluation of the health of the tendons was 
made based on lack of abnormalities on physical examination and gross appearance of the 
tendon on cross section. There were five geldings, two mares and two stallions. Breeds 
represented included one pony, one Thoroughbred, five Quarter Horses and two American 
Paint Horses. The tendon segments were placed in Hank's balanced salt solution• for 
transport to the laboratory for further processing. 
Tendon fibroblasts were isolated via primary explant culture ( 15). The paratenon and 
epitenon were removed by trimming the outer 1-2 mm of tissue from all four sides of the 
tendon specimen. The tendon was minced into 1-2 mm3 fragments of tissue wruch were 
placed 5-6 mm apart in 25 cm2 flasks. Growth medium [MCDB I 05• or Dulbecco's Modified 
Eagle's Medium, rugh glucoseb (DMEM), l 0% foetal bovine serumc (FBS), l % gentamicin" 
and 20 ng/ml recombinant human insulin-like growth factord] was added to each flask to cover 
the tissue fragments (explants). The flasks were incubated in 5% C02 and humidified air at 
37°C for 14 days. Growth medium was changed every four to five days. 
On day 14 the growth medium and explants were removed. Fibroblasts were 
trypsinized with 0.05% trypsin with 0.2% ethylenediaminetetraacetic acid in saline A (ATV). 
The flasks were rinsed with ATV to remove serum. The ATV was discarded and fresh A TV 
was added to each flask. The flasks were placed on the 37°C heating block fo r 30-60 seconds 
and the ATV was immediately removed and discarded. Then the flasks were replaced on the 
•sigma Chemical Co., St. Louis, MO 
bGIBCO Laboratories, Grand Island, NY 
csummit Biotechnology, Fort Collins, CO 
dFisher Scientific, Itasca, IL 
15 
37°C heating block for an additional one minute, until the cells were released. The sides of the 
flask were rapped intermittently to aid in cell detachment. Medium was added to the flask to 
arrest the trypsinization and the newly trypsinized cells were seeded to new 25 cm2 flasks or 
12 well plates. Subcultures were performed using the same trypsinization protocol. 
Following trypsinization, each flask was divided into two new flasks (split 1 :2). Medium was 
changed every four to five days. The monolayers were studied as described below. 
In preparation for light and transmission electron microscopy (TEM), the monolayers 
were then rinsed with phosphate buffered saline (PBS). For light microscopy, the cells were 
fixed with 95% ethanol for five minutes and stained with l .2% aqueous crystal violet solution. 
For TEM the cells were fixed in 3% glutaraldehyde for 15 minutes then scraped into a pellet 
while in the 3% glutaraJdehyde. The cell pellet was processed in a standard protocol for TEM 
(28) and the samples were examined by TEMc. 
Cryopreservation was performed using complete monolayers of equine tendon 
fibroblasts . These cells were also trypsinized, as previously described. Cells were suspended 
in growth medium supplemented with 10% dimethyl sulfoxide at approximately 6.0 X 106 
cells/ml in cryovials. The vials were placed in a cell-freezing container (NaJgene Cryo 1°C 
Freezing Container') to allow the cells to freeze at 1°C/min to -70°C. After 24 hours at -70°C 
the cryovials were transferred to liquid nitrogen storage. 
The cells were thawed rapidly in a 34°C water bath and the cell suspension (1 ml) from 
one cryovial was added to 5 ml of culture medium containing 10% FBS, 1 % gentamicin and 
30 µl/ml of I 0% lactalbuminhydrolyzate" in a 25 cm2 flask . The flasks were pre-coated with 
either 5 µglm1 of recombinant human fibronectin• or collagenr. All of the spent medium was 
exchanged with standard growth medium 12-24 hours after thawing and standard subculture 
techniques were employed thereafter. 
Proteoglycan production was measured in two distinct fractions: cell-free 
(supernatant) and cell-associated (from the monolayer). First passage cells from five of the 
nine horses were seeded into 12 well plates and incubated in 5% C02 and humidified air at 
cHitachi, San Jose, CA 
rVitrogen 1 OOTM' Flow Laboratories, McLean, VA 
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37°C for 48 hours. Next the cells were incubated with growth medium contai ning 40 µCi/ml 
of Na/ 5S048 for 24 hours at 37°C in 5% C02 and humidified air. Proteoglycan production 
was determined by guanidine hydrochloride (GnHCI) extraction, cetylpyridinium chloride 
(CPC) precipitation, and liquid scintillation counting (5,6). The supernatant fraction was 
removed from each well. and stored at 4°C in individual microcentrifuge tubes. Proteoglycans 
were isolated from the cell-associated fraction by extraction in 4M GnHCI (0 .05M sodium 
acetate and protease inhibitors, pH 5. 8)3 (5,6). Extractions were performed for 48 hours at 
4°C. Precipitation of proteoglycans was completed by spotting I 00 µ I of GnHCI extraction 
solution or supernatant on filter paper and dipping the filter papers in 0 .1 % CPC" in 0.3M 
sodium chloride for 30 minutes. Unincorporated isotope was removed by three sequential 
washes in the same solution . 
Each filter paper was placed in an individual glass scintillation vial containing 
scintillation fluidd. Proteoglycan content was determined using a liquid scintillation counter'. 
Results were reported per well of a 12 well plate ( 4 cm2) . Counts were converted from 
counts per minute to disintegrations per minute (DPM) based on the efficiency of counting of 
the machine as calculated via a control sample. Cell-associated and supernatant fraction 
counts were multiplied by factors of two and I 0 respectively to adjust for the portion of the 
total volume that was spotted onto the filter paper. 
Results: 
The cells migrated out of the explants from all of the horses and formed a visible halo 
of cells by ten days fo llowing the initiation of cultures. They continued to migrate and divide, 
expanding the diameter of the halo through 14 days. By 14-17 days in culture, adequate 
numbers of cells were in monolayers to permit proceeding with trypsinization. The cells were 
able to establish secondary monolayers within three days following trypsinization . The 
population of cells migrating out of the explants was morphologically consistent with 
fibroblasts . None of the cells appeared to possess phagocytic characteristics (i.e. no cells 
81.CN Pharmaceuticals, Irvine, CA 
hPackard Instrument Company, Meriden, CT 
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were found to contain nuclei or nuclear detritus in cytoplasmic vacuoles). 
By light microscopy, two primary shapes of fibroblasts were identified. The cells 
along the more sparsely populated margin of the halo were stellate in shape (Figure 2.1). 
Each cell had several cytoplasmic processes extending from the center of the cell. Those in 
the more densely populated areas demonstrated an elongated spindle shape (Figure 2.2) . Both 
types of cells had large centrally located oval nuclei with several large nucleoli. Other types of 
cells were not identified. As maintenance of the cultures continued, the cells dedifferentiated 
toward the more spindle-shaped type of cell. The time required to form a secondary 
monolayer was prolonged to four to five days. 
Electron microscopy confirmed that the cells were fibroblasts . The cell morphology, 
and ability to produce extracellular matrix products, are characteristic of fibroblasts . Rough 
endoplasmic reticulum was abundant and it was characterized by distended cisternae 
containing finely granular material. Numerous membrane-associated pinocytotic vesicles were 
common. Proteoglycan and collagen were present in the extracellular space adjacent to the 
cell membrane. Proteoglycan appeared as an amorphous mass of material. Collagen fibers 
were identified as linear filaments aligned with each other and parallel to the cell membrane 
(Figure 2.3). 
The equine tendon fibroblasts were very sensitive to trypsinization by routine 
techniques. Standard protocols for the trypsinization of epithelial cells resulted in complete 
detachment of the tendon cells and subsequent poor viability. By reducing the contact time 
with the ATV from three to five minutes to 30-60 seconds, the cells remained viable for 
multiple subcultures and demonstrated the capacity for continued cell division up to ten 
subcultures. After the fourth subculture, an increasing number of cells failed to reattach 
following each subsequent trypsinization. Attachment was improved significantly by coating 
the culture dishes with collagenr prior to seeding. 
Initial efforts at cryopreservation of the cells resulted in low cell viability. Cell 
counting was not performed. Losses resulted primarily from failure to attach to the flask 
when human recombinant fibronectin• was used to coat the flasks . Pretreatment of the 
plasticware with collagenr rather than fibronectin improved attachment dramatically. Viability 
rates were nearly 100% and cells were successfully subcultured for up to nine passages after 
Figure 2.1 . 
I 
~ .: 
· ·~· : , ' 
• i 
4" -... 
18 
..., . ., . 
'· 
Photomicrograph of equine tendon fibroblasts demonstrating the ste llate cells 
characteristi c of the more sparsely populated areas (crystal vio let stain, 
approx imately 70x). 
Figure 2.2. 
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Photomicrograph of equine tendon fibroblasts demonstrating the spindle shape 
cell s characteristic of densely populated areas (crystal violet stain, approx imately 
70x). 
Figure 2.3 . 
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Transmission electron micrograph of equine tendon fibroblasts. Note the 
abundant rough endoplasmic reticulum with dilated cistemae containing granular 
material (arrow head) and extracellular matrix between the cells (A) 
(approximately 13X103x). 
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thawing. Thawed cells maintained their characteristic fibroblastic appearance and their ability 
to produce proteoglycan. 
Radiolabel studies confirmed that the equine tendon fibroblasts were capable of 
producing proteoglycan in measurable amounts. Proteoglycan was present in both the cell-
associated fraction and in the supernatant (Table 2.1 ). 
Table 2.1. Sulfated proteoglycan content in the cell-associated and supernatant 
fractions from cultures of tendon fibroblasts after labeling with Na/ 5S04 
Block # Fraction DPM x 103 
Cell-Associated 11.6 
Block # I Supernatant 28.6 
Cell-Associated 14.8 
Block #2 Supernatant 41.3 
Cell-Associated 31.1 
Block #3 Supernatant 98.3 
Cell-Associated 25 .1 
Block #4 Supernatant 82.0 
Cell-Associated 23 .5 
Block #5 Supernatant 89.0 
Discussion: 
Our results are consistent with those reported in cattle ( 43 ,44), chicken (38), rabbit 
(1 ,9) and humans (7) with regard to the ability to isolate viable fibroblasts from tendon tissue 
and maintain them in cell culture. Cells were isolated from the tissue via out-growth of 
migrating cells. This technique was selected over tissue digestion methods in order to 
maximize the numbers of viable cells isolated. Enzymatic degradation of tendon is laborious, 
requiring many hours of processing (9,44). Poor cell viability following enzymatic 
degradation has been reported (9) The migration technique worked well. The system 
described is simple and yields a more than adequate number of healthy, metabolically active 
cells. 
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Regardless of the method employed to isolate cells, there is a degree of inherent 
selection for a certain cell type. When enzymatic degradation is used, only those cells that 
survive the disaggregation technique and adhere to the substrate or survive in suspension are 
propagated. The migration technique inevitably selects for the subset of cells contained within 
the explant that are capable of migration. Although there are advantages and disadvantages of 
any culture system, we feel that the selection by migration is beneficial in this model, because 
fibroblast migration is an accepted portion of the tendon healing process (2,7, 19,26). 
Radiolabel studies have documented fibroblast migration from a site distal to an injury (3 1 ). 
We speculate that the cells capable of migration from the tissue explants are the same cells 
that are responsive to injury in vivo (7). 
The equine tendon fibroblasts isolated in this study were very sensitive to 
trypsinization. Prolonged contact with ATV resulted in decreased attachment and cell 
viability. Through repeated trials the protocol presented here in consistently removed the cells 
from the plastic, without irreversible cell damage or loss when the trypsin was removed and 
discarded. Scraping the cells off the flasks, followed by centrifugation, resulted in poor cell 
viability and excessive cell clumping due to the trauma of the scraping and the centrifugation. 
Fibroblasts are known to be anchorage dependent (15) . Standard polystyrene culture 
dishes are a suboptimal environment for attachment. Collagen and fibronectin are available 
commercially for coating of the plastic culture dishes prior to cell seeding . In particular in our 
laboratory, we observed improved attachment using a commercially available collagen 
producf. Coating the plates for the initial explant phase was unsuccessful because the tissue 
fragments did not remain adhered to the plastic; the detached cell s lacked a surface for 
migration. 
Fibroblasts can vary in shape based on location, the nature of the substrate to which 
the cell adheres, or in response to different culture conditions (12, 15,23,31) . When viewed by 
light microscopy, cells in our culture system demonstrated two distinct shapes. It is uncertain 
whether these shapes represent two distinct cell types or simply two morphological alterations 
of the same population of cells. The cell morphology appears to be heavily influenced by the 
cell density. T hey start out in the stellate form in early cell cultures, immediately following 
attachment and during migration out of the explants. As the cell density increases and the 
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cultures become more mature a gradual transformation to the more spindle shape is noted. 
Three types of tenocytes have been described in normal equine tendon. They have not 
yet been characterized (25). Identification of unique cell surface markers would be useful to 
further characterize the cell types described in vitro and in normal equine tendon (16) . The in 
vitro populations of cells could then be compared to the in vivo population of tenocytes. The 
identification of individual cell types may aid in the further subculture of cells to study their 
individual responsibilities with regard to tendon healing . This is important because distinct 
cell types may produce different cell products and have different roles in the healing process. 
Equine tendon fibroblasts survived multiple cell generations; however, repeated 
subculturing has several disadvantages. First, the tendon fibroblasts become increasingly 
dedifferentiated with progressive subculturing. Second, each successive passage of cells 
creates a larger difference between the in vivo and in vi fro characteristics of the fibroblasts, 
with regard to their metabolic activity. Third, this system does not allow for the influence of 
the extracellular tendon matrix environment or the effect of mechanical forces to help maintain 
the differentiated cell type (15,22). 
Multiple factors act on individual cells to produce a specific phenotype. In tissue 
culture systems, these factors may be altered and cells may change their phenotype. 
Dedifferentiation is defined as the loss of specific phenotypic properties associated with the 
mature cell in vivo (15). When these phenotypic changes occur it can either be an adaptive 
process (the differentiated phenotype may be regained) or a selective process (a precursor cell 
has been selected over the differentiated cell type). 
Maintaining phenotype and preventing dedifferentiation is an important issue in tissue 
culture systems that are a model for a clinical problem. Our model, as described, did not 
allow for clonal selection of phenotypically distinct populations of tenocytes because the cells 
rapidly dedifferentiated toward one phenotype. Cell surface markers may help identify and 
sort the different cells. 
There are two possible sources of the cells that have been isolated in this model. They 
may be actual tenocytes from the tissue parenchyma, they may originate from the endotenon 
or be a combination of these two sources may be represented. Care was taken to remove the 
paratenon and epitenon in order to avoid contamination of the cultures by cells from these 
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sources. The endotenon is an intricate network of connective tissue fascicles that organize the 
tendon fibers into bundles. Because of the nature of this intrinsic tendon structure, it is 
impossible to remove all of the endotenon and any remaining endotenon could act as a cell 
source. 
The cultured cells were successfully cryopreserved. This means that tendon fibroblasts 
can be stored for future investigations. The value in cell storage is the ability to accumulate 
experimental material from clinical cases in sufficient numbers over an extended period of time 
to obtain statistically significant results. Cryopreservation allows for simultaneous studies to 
be done on cell lines isolated from different horses, ensuring that experimental conditions are 
the same for each cell line . For example, cell lines could be compared between young and old 
horses or lines from horses with SDF lesions which had healed well compared to those from 
horses with lesions which healed poorly. 
Proteoglycan concentrations were approximately 2.5-3 .5 times higher in the 
supernatant than in the cell-associated fraction. Proteoglycan measured in the cell-associated 
fraction can be intracellular or incorporated into the extracellular matrix immediately adjacent 
to the cells ( 45) . Additional studies would be necessary to determine the relative amounts of 
intracellular and matrix-associated proteoglycans in the cell-associated fraction ( 45). Based 
on our results, it is presumed that the majority of extracellular proteoglycans produced by 
cultured tenocytes are distributed as soluble molecules in the supernatant. 
There are several advantages of in vitro cell cultures in the investigation of clinical 
tendinitis : l) Cell culture provides a homogeneous population of cells replicating uniformly 
for assignment to treatment groups, 2) Jn vitro models simplify biological effects and allow 
precise environmental control, 3) Monolayer culture isolates fibroblasts from the influences of 
the extracellular matrix, other cell types and cell products present in explant systems, and 4) 
Cellular responses can be monitored on a biochemical and ultrastructural level. In addition, in 
vitro research can be less expensive because of the reduced costs of housing and maintaining 
animals . Finally, the need for animal sacrifice is reduced, which is ethically appealing. 
In conclusion, equine tendon fibroblasts can be grown as monolayers and these tendon 
fibroblasts are capable of extracellular matrix production. This model will be valuable in 
future studies of certain aspects of tendon healing. Further work is required in the area of the 
25 
quantitation and characterization of collagen production. There is also the need to further 
characterize the tendon cell types encountered . This model will be used to investigate the 
effects of pharmaceuticals including PSGAG and HA on tendon fibroblast metabolism and 
matrix production. 
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CHAPTER 3. THE EFFECT OF POLY ULFATED GLYCOSAMINOGLYCAN ON 
PRODUCTION OF PROTEOGLYCAN BY EQUINE TENDON FIBROBLASTS lN 
MONOLA YER CULTURE 
A paper submitted to Veterinary and Comparative Orthopaedics and Traumatology 
Linda A. Dahlgren, Ricardo F. Rosenbusch, Larry C. Booth 
Summary: 
Equine tendon fibroblasts were isolated from tissue fragments of superficial digital 
flexor tendon, subcultured and maintained in monolayers. The cells were treated with two 
dosage regimes of polysulfated glycosaminoglycan (PSGAG). The high dose group received 
0, 25, 50 or 200 µglm1 of PSGAG and the low dose group received 0, 0.3, 1 or 2 µglml of 
PSGAG. Proteoglycan production was measured via liquid scintillation counting following 
radiolabel with 35S04 ( 40 µCi/ml). Counts were measured in both the cell associated fraction 
and the supernatant fraction. 
Addition of PSGAG to the culture system did not adversely affect cell viability at any 
treatment level. Cells in all treatment groups produced measurable amounts of proteoglycan 
in both the cell associated and supernatant fractions. There were no differences between 
treatment means in any of the four groups (high dose cell-associated, high dose supernatant, 
low dose cell-associated, low dose supernatant) . No linear trend in proteoglycan production 
was documented between treatment groups in either the cell-associated or supernatant 
fractions for either of the two dosage regimes. The significance of the lack of effect is 
uncertain. PSGAG may influence tendon healing in a manner other than by increasing 
proteoglycan production. 
Introduction : 
Tendinitis of the digital flexor tendons is a common problem in athletic horses. The 
high frequency of injury and the extended healing time required for rehabilitation of equine 
tendon injuries have stimulated an interest in developing treatments that will improve the rate 
and quality of tendon healing. One of the treatments currently being investigated is the use of 
30 
polysulfated glycosaminoglycan (PSGAG). Systemic administration of a commercially 
available PSGAGa improved the quality and rate of tendon healing in a collagenase-induced 
tendinitis model (22). In another report, it was suggested that intramuscular or peri-lesional 
injection of PSGAGb in horses benefited tendon healing (12) and in a single case report it was 
suggested that intralesional PSGAGb in the horse was beneficial to healing (24). In humans, 
PSGAGc has been used successfully to treat Achilles peritendinitis by local injection (26). The 
mechanism of action of PS GAG with regard to tendon healing is uncertain. 
Polysulfated glycosaminoglycan is a polymeric chain of highly sulfated 
glycosaminoglycans. The major component is chondroitin sulphate (5). It has a molecular 
weight of 2,000 to 16,000 daltons and is extracted from bovine lung and trachea (5). 
Polysulfated glycosaminoglycan has been studied extensively in several species for its effects 
on cartilage (3,5,6, 7,9, 11,15,25,27-29). It is marketed for the treatment of degenerative joint 
disease and is reported to promote the synthesis ofhyaluronic acid (3,20,23,30), cartilage 
matrix components and collagen (11 ). Polysulfated glycosaminoglycan also inhibits the action 
of several catabolic enzymes such as neutral metalloproteases (10, 15, 19). 
The similarities in matrix constituents between cartilage and tendon suggest that some 
of the beneficial effects of PSGAG documented in cartilage studies may also be expected to 
occur in tendon. The ground substance of both tendon and cartilage are constructed of 
proteoglycan complexes of glycosaminoglycan side chains attached to a protein core and 
linked by another protein to hyaluronate. The primary differences between cartilage and 
tendon lie in the distribution of specific glycosaminoglycans and the orientation of the collagen 
fibers. 
The purpose ofthis study was to investigate the effect of PSGAG on the production of 
proteoglycans by equine tendon fibroblasts and the mechanism of action by which PSGAG 
may improve tendon healing. A previously described in vitro model was utilized to 
aAdequan, Luitpold Pharmaceuticals, Shirley, NY 
b Adequan, Panpharma, Hayes, UK 
c Arteparon, Luitpold-Werk, Munich, Germany 
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accomplish this goal (8) . 
Materials and Methods: 
The middle one third of the superficial digital flexor tendons were harvested aseptically 
from the forelimbs of five horses (two to 14 years old) immediately following euthanasia. 
Horses were euthanatized for reasons other than tendinitis. Evaluation of the health of the 
tendons was made based on lack of abnormalities on physical examination and gross 
appearance of the tendon on cross section. There were two geldings, one mare and two 
stallions. Breeds represented included three Quarter Horses and two American Paint horses. 
The tendon segments were placed in Hank's balanced salt solutiond for transport to the 
laboratory for further processing. 
Tendon fibroblasts were isolated via primary explant culture as described in a previous 
study (8). Following removal of the paratenon and epitenon, the tendon was minced into 1-2 
mm3 fragments of tissue which were placed into 25 cm2 flasks. Growth medium (Dulbecco's 
Modified Eagle's Medium, high glucose (DMEMY, 10% fetal bovine serumr, 1 % gentarnicind 
and 20 ng/ml recombinant human insulin-like growth factor') was added to each flask to cover 
the tissue fragments. The flasks were incubated in 5% C02 and humidified air at 3 7° C for 14 
days . Growth medium was changed every four to five days. 
On day 14 the growth medium and explants were removed. Fibroblasts were 
trypsinized as previously described (8) and seeded into 12 well plates at an approximate 
density of 1. 5 x 104 cells/cm2. The cells were reincubated in 5% C02 and humidified air at 
37°C for 48 hours until a rapidly dividing monolayer covered approximately 80% of each well. 
The standard growth medium was exchanged with fresh medium containing PSGAG1 in 
concentrations ranging from 0 to 200 µglml. The concentrations of PSGAG were grouped 
dSigma Chemical Co., St. Louis, MO 
cGIBCO Laboratories, Grand Island, NY 
rsummit Biotechnology, Fort Collins, CO 
gpisher Scientific, Itasca, IL 
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into high and low dosage regimes of four treatment levels each: (I) high dose (0, 25, 50 and 
200 µg/ml) and (2) low dose (0, 0 .3, I and 2 µ g/ml). Each treatment was perfo rmed in 
quadruplicate. Five horses were used for the high dose groups and three horses were used for 
the low dose groups. The cells were incubated in the presence of PS GAG" for 48 hours and 
then labeled with 40 µCi/ml ofNa,/5SO/ for an additional 24 hours at 37°C in 5% C01 and 
humidified air (8). 
Proteoglycan production was measured in two distinct fractions: cell-free 
(supernatant) and cell-associated (from the monolayer) by guanidine hydrochl oride extraction 
and cetylpyridinium chloride precipitation (6-8). Proteoglycan content was determined using 
a liquid scintillation countef. Results were reported per well of a 12 well plate ( 4 cm2) in 
disintegrations per minute (DPM) based on a factored adjustment for the proportion of the 
total volume spotted onto the filter paper (8) . 
Statistics were performed on the means fo r each treatment level. Differences in 
proteoglycan production at the four levels of PSGAG treatment (within the high or low 
treatment group) were tested using the analysis of variance procedure, each horse comprising 
an experimental block. The presence of a linear trend with dose was also tested fo r each of 
the four groups of results (high dose cell-associated, high dose supernatant, low dose cell-
associated, low dose supernatant) . Significance was established at p<0.05 . 
Results: 
Cells were successfully harvested from all five horses utilized in this study. The cell s 
migrated out from the tissue fragments in adequate numbers by 14 days in culture to seed the 
necessary number of monolayers for control and treatment groups. Secondary monolayers 
were established within two days . Addition of PSGAG to the culture medium did not 
adversely affect cell viability at any treatment level. The cells maintained the two primary 
shapes described in a previous study fo llowing treatment with PSGAG (8) . Subjectively, cells 
treated with PSGAG appeared to proliferate more rapidly than the cells in the control wells. 
hICN Pharmaceuticals, I rvine, CA 
;Packard Instrument Company, Meriden, CT 
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Cells in all eight treatment groups produced measurable amounts of proteoglycan in 
both the cell-associated fraction and in the supernatant (Tables 3.1, 3.2, 3.3 and 3.4). There 
were no differences between treatment means in any of the four treatment groups (high dose 
cell-associated, high dose supernatant, low dose cell-associated, low dose supernatant). No 
linear trend in proteoglycan production was documented between treatment groups in either 
the cell-associated or supernatant fractions for either of the two different dosing regimes. The 
variations between horses was very large. Counts were generally 3. 5 times higher in the 
supernatant fraction than in the cell-associated fraction for each treatment. 
Discussion: 
The use of PSGAG in the treatment of degenerative joint disease has been studied 
extensively in the dog, horse, pig, human, chicken and rabbit (1-3 ,6,7, 11 , 16,31). Polysulfated 
glycosaminoglycan is reported to stimulate the biosynthesis of extracellular matrix 
proteoglycans and has a chondroprotective effect (2, 10, 13, 15, 18). Studies evaluating the 
effects of PS GAG on equine cartilage have shown inconsistent results. One in vitro study 
demonstrated both increased cell replication and increased production of extracellular matrix 
when normal and arthritic equine cartilage was treated with PSGAG (11). Subsequent studies 
were unable to reproduce Glade's results (6, 7). Polysulfated glycosaminoglycan caused a 
small but significant decrease in proteoglycan synthesis and failed to prevent cartilage 
degradation in normal and osteoarthritic cartilage tissue explants (6, 7). 
Despite these mixed results in vitro, PSGAG has shown promise clinically in the 
treatment of osteoarthritis (3 , 13,27) and more recently in the treatment of tendinitis in 
humans and horses (12,21 ,22,26). Our results failed to support increased proteoglycan 
production as the mechanism by which PSGAG modulates tendon healing. We were unable 
to document any effect on proteoglycan production by equine tendon fibroblasts incubated 
with various levels of PSGAG. 
Polysulfated glycosaminoglycan may influence tenocyte metabolism by a mechanism 
other than the stimulation of total proteoglycan production. In vitro studies have shown 
PSGAG to stimulate the synthesis of collagen, hyaluronic acid and proteoglycan 
(3 ,5, 11 ,20,30). No effect on proteoglycan production was measured in this study. Perhaps 
Table 3. 1. 
Level of 
PSGAG 
(µg/ml) 
0 
25 
50 
200 
Table 3.2. 
Level of 
PSGAG 
(µg/ml) 
0 
25 
50 
200 
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Sulfated proteoglycan content in the cell-association fraction after labeling with 
Na/ 5S04 . All counts are reported as DPM X 10
3
. SEM = 8.6. 
Block Block Block Block Block Treatment 
#1 #2 #3 #4 #5 Means 
14.8 30.9 25 .1 23.4 42.0 27.2 
13 .7 23 .6 26.9 20.3 54.6 27.8 
13 .3 25.4 29.2 22.3 38.2 25.7 
12.0 25.5 23 .0 23 .1 32.8 23.3 
Sulfated proteoglycan content in supernatant fraction after labeling with 
N~35S04 . All counts are reported as DPM X 103. SEM = 2.0. 
Block Block Block Block Block Treatment 
#1 #2 #3 #4 #5 Means 
41.3 100.5 82.0 88.6 136.9 89.9 
54.5 93 . 1 95.0 128.5 83 .5 90.9 
51.1 105.4 86.8 114.6 82. l 88.0 
48.9 90.0 69.2 142.2 75 .8 85.2 
Table 3.3. 
Level of 
PSGAG 
(µg/ml) 
0 
0.3 
1 
2 
Table 3.4. 
Level of 
PSGAG 
(µg/ml) 
0 
0.3 
1 
2 
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Sulfated proteoglycan content in cell-associated fraction after labeling with 
Nctz35S04. All counts are reported as DPM X I 0
3
. SEM = 12.8 
Block Block Block Treatment 
# 1 #2 #3 Means 
31.3 23 .4 42.0 32.2 
36.2 2 1.5 33.4 30.4 
31.1 2 1.4 34 .2 28.9 
27.2 19.8 29.4 25.5 
Sulfated proteoglycan content in supernatant fraction after labeling with 
Nctz35S04. All counts are reported as DPM X 10
3
. SEM = 1.5. 
Block Block Block Treatment 
# 1 #2 #3 Means 
96.1 88.6 136.9 107.2 
104.8 128.5 80.2 104.5 
102.5 11 4.6 77.9 98.3 
106.4 142.2 78.5 109.0 
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PSGAG exerts its beneficial effects on tendon healing through the modulation of collagen or 
hyaluronic acid synthesis. Polysulfated glycosaminoglycan may influence tendon healing by 
inhibiting the activity of the collagen degrading enzymes such as lysosomal enzymes, neutral 
proteases, stromelysin and elastase (2, 13, 15, 18, 19). Data collection in this study was limited 
to the measurement of total proteoglycan production. Further studies investigating the 
production of collagen and hyaluronic acid and the inhibition of proteolytic enzymes will be 
valuable. 
Normal tissues were selected for use in this model; however, it is possible that 
damaged tendon tissue would be more responsive to treatment with PSGAG. Arthritic 
cartilage was more sensitive to the effects of PSGAG than normal cartilage (11 ) . An in vitro 
study investigating the effects of PS GAG on hyaluronic acid (HA) production by human 
synovial fibroblasts demonstrated a much greater stimulation of HA synthesis in rheumatoid 
cells than in normal cells (23). 
The effects of PS GAG as investigated within the constraints of this model are limited 
by the nature of the model. Factors that are not reproduced in the laboratory may have a 
positive influence on the cells in vivo. By measuring proteoglycan production in clinical cases 
of tendinitis treated with intramuscular or perilesional PSGAG, a positive effect may be 
demonstrated. 
The optimal dose of PSGAG required for tendon healing is not known. Drug 
concentrations in the microgram per milliliter range were selected over those in the milligram 
per milliliter range for this study. These dosages were based on previous in vitro studies 
involving equine cartilage (6, 7) . We were successful in growing the cells at these 
concentrations (25, 50 and 200 µg/ml) . 
Doses for the second, lower dose regimen, were extrapolated from the tissue levels 
measured in serum and synovial fluid following intramuscular injection of tritium-labeled 
PSGAG ( 4, 14). Levels of PS GAG that are achieved in tendon following intramuscular 
injection have not been established; however, for the purposes of this study they were 
assumed to be similar to serum and synovial fluid . Levels of PSGAG in serum and synovial 
fluid peaked at two hours post-injection at 1.96 and 0.33 µglml respectively. Levels of 0.3 - 1 
µglml are reported to be adequate to stimulate proteoglycan synthesis in diseased articular 
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cartilage (17). Based on this information, levels of 0.3, 1 and 2 µglml PSGAG were selected 
for the lower dosing regimen. No difference in effect was seen with either the high or low 
dosage regimes. The lack of effect reported in this study may be related to the selection of 
drug concentrations that are not optimal for influencing an increase in proteoglycan 
production. 
The apparent lack of effect of PS GAG on proteoglycan production may be an 
indication that PSGAG is influencing tendon healing in a manner other than by an increase in 
total proteoglycan production. Further studies are necessary to measure collagen production, 
matrix degradation and cell division in an effort to identify the mechanism by which PSGAG 
improves tendon healing. 
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CHAPTER 4. GENERAL CONCLUSIONS 
The research presented in this thesis establishes the groundwork for further 
investigations into the modulation of tendon healing. We have established that equine tendon 
fibroblasts can be consistently isolated, maintained, cryopreserved and subcultured using the 
explant culture system described. The cultured tendon fibroblasts were capable of producing 
proteoglycan in measurable amounts both before and after cryopreservation. Evidence of 
collagen production was demonstrated via electron microscopy. 
Two primary cell morphologies were documented. The cell shapes appeared to be 
influenced by the surrounding cell density. In areas of decreased cell density, stellate cells 
were characteristic. As the monolayers became more complete, the cells adopted a spindle 
shape. The precise implications of this observation are uncertain; however, future work 
characterizing the cells using surface markers and monoclonal selection will provide more 
specific information with regard to the specific cell types present within tendon. An 
understanding of the cell types and their individual functions in the maintenance of normal 
tendon matrix will improve the ability to modulate tendon healing. 
Much of the initial time and effort expended in completing the work for this thesis was 
in working out the details of the culture system. The cells were unusually sensitive to 
trypsinization, necessitating the investigation of alternate techniques to minimize cell loss and 
to maximize cell adherence following trypsinization. The techniques that have evolved 
produce consistent results with good cell viability. The basic culture model work provides the 
basis from which other studies may be designed. 
The study investigating the effect of PSGAG on proteoglycan production by the 
cultured tenocytes is the first of what will, hopefully, be many such studies. We were able to 
demonstrate that the cells maintained their viability and ability to produce proteoglycan 
following addition of PSGAG to the culture medium. At the doses selected, we were unable 
to show any effect on proteoglycan production. We did find a very large variation between 
individual horses in the amount of proteoglycan produced and in the response of the individual 
populations of cells to the PSGAG. Perhaps with a larger number of replications we may 
have been able to demonstrate a stati stically significant trend. 
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The model developed and described will serve as a research tool in better 
understanding the physiology of tendon healing. Future studies involving the effect of 
PSGAG on collagen production, tenocyte replication and hyaluronic acid production will be 
necessary to elaborate the mechanism of action of this drug on tendon healing. The effects of 
PSGAG on diseased tendon tissue is also of interest. Other potential medications may be 
evaluated in a similar manner utilizing this model. A more thorough understanding of tendon 
healing is essential before we can expect to successfully improve the quality and rate of tendon 
healing via pharmacological or physical therapy means. 
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APPENDIX A. SUPPLEMENTAL MATERIALS AND METHODS 
Media and stock solution preparation 
Hank's Balanced Salt Solution (HBSS), MCDB-105 medium (MCDB), Dulbecco's 
Modified Eagle's Medium (DMEM) and insulin-like growth factor I (IGF-1) were mixed and 
prepared as per enclosed manufacturers ' instructions. They were filter sterilized where 
indicated, stored in the refrigerator and opened only in the laminar flow hood to maintain 
sterility. The IGF- 1 was stored in 0.5 ml aliquots at -20° C and thawed as needed. 
Growth medium was used for all culture conditions and was prepared fresh each day 
prior to planned laboratory procedures. The total amount of growth medium required for the 
day was calculated and appropriate volumes of fetal bovine serum (FBS), gentamicin and 
IGF-1 were added to the calculated volume of stock medium (MCDB or DMEM) to achieve 
concentrations of 10%, 1 % and 20 ng/ml respectively. One 0 .5 ml aliquot of diluted (lµ g/ml) 
IGF-1 was added per 24 ml of medium to achieve 20 ng/ml . The prepared growth medium 
was warmed to 36° C in a water bath prior to use. 
Guanidine hydrochloride extraction/cetylpyridinium chloride precipitation 
Stock solutions of protease inhibitors were made ahead of time and used to make a 
fresh solution of 4M guanidine hydrochloride with protease inhibitors prior to each extraction. 
A solution of 4M guanidine hydrochloride with protease inhibitors was made by mixing 3.82 g 
guanidine hydrochloride in 4 ml of distilled water and adding the following stock solutions: 
250 µ l sodium acetate (2M), 100 µ l phenylmethyl-sulfonylfluoride (lmM), 1.0 ml disodium 
EDTA (1 OmM), 100 µ l benzamidine (1 mM) and 100 µl N-ethylmaleide (1 mM). The solution 
was completed by adding 0.131 g [-aminocaproic acid in the powder form to make a 100 
mM solution of [-aminocaproic acid. The total volume was increased to 10 ml and the pH 
was adjusted to 5.8 using lN sodium hydroxide. Stock solution preparation for the protease 
inhibitors and the cetylpyridinium chloride precipitation are described in table A 1. 
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Table A 1. Mixing instructions for stock solutions. RT = room temperature, FS = filter 
sterilize, dH20 = distilled water, QS = bring volume up to, NaOH = sodium 
hydroxide. 
Stock Solution Weight DiluentN olume Storage Comments 
0.3M sodium chloride 19.5 g 1 liter dH20 RT FS 
(NaCl) 
0.1 % cetylpyridinium 500 ml 0.3M RT warm prior to use 
chloride (CPC) 500 mg NaCl to resuspend 
FS pH to 5.8 using 
2M sodium acetate 16.4 g 100 ml dH20 RT glacial acetic acid 
100 mM phenylmethyl-
sulfonylfluoride 1.74 g 10 ml methanol -20° c 
FS (0.2µ ) pH to 5.8 using 
1 OmM disodium EDT A 18.6 g 500 ml dH20 4° c IONNaOH 
1 mM benzamidine Add 9 .4 ml dH20 2 ml aliquots 
hydrochloride 156 mg Mix/QS to 10 ml -20° c 
Add 8-9 ml dH20 
lrnM N-ethylmaleide 125 mg Mix/QS to 10 ml RT 
Initially, a protocol was devised to precipitate all proteins in the supernatant using 
trichloroacetic acid (TCA) prior to the guanidine hydrochloride extraction of the 
proteoglycan. Two hundred rnicroliters of cold 60% TCA was added to I ml of medium to 
achieve a I 0% solution. This solution was incubated for one hour or overnight at 4° C. 
Samples were kept on an ice bath at all times. The samples were centrifuged at 4° C for five 
minutes in the microcentrifuge. The supernatant was drawn off and discarded. One hundred 
micro liters of the 4M guanidine hydrochloride protease inhibitor solution was added to each 
tube and mixed. Tubes were placed on a spinner in the refrigerator at 4° C for 48 hours. The 
samples were then spotted on filter paper for the CPC precipitation as described for the cell-
associated fraction in Chapter 2. Further investigation obviated the need for TCA 
precipitation. The proteoglycans were extracted and precipitated directly to from the 
supernatant as described in Chapter 2. 
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Cell attachment factors /collagen coating of plasticware 
Standard culture flasks and dishes provide a suboptimal environment for fibroblast 
attachment. Following trypsinization, a large number of cells were lost because they were 
unable to anchor themselves to the plastic of the flasks. Several commercial products were 
evaluated in an effort to improve cell attachment. Vitrogen 100, a commercial collagen 
product, and five other attachment factors were evaluated. 
In the laminar flow hood, enough Vitrogen I 00 was added to each flask or well to 
completely coat the bottom using slow gradual swirling motions so as not to fragment the 
collagen fibers . The excess liquid was removed by pipetting and the flask or plate was 
allowed to sit uncovered overnight in the laminar flow hood until completely dry. The 
container was then rinsed with sterile distilled water and allowed to dry in the laminar flow 
hood overnight. Coated containers were sealed and stored in the refrigerator until used. The 
additional preparation of rinsing the flasks was necessary prior to usage to insure a dry surface 
for explant adherence. Use of phosphate buffered saline (PBS) to rinse the flasks should be 
avoided because the dried salt forms a potentially cytotoxic layer on the surface of the plastic 
when the PBS dries. 
Each of the commercial plates that were evaluated were coated with one of five 
different attachment factors : ( 1) human fibronectin, (2) poly-0-lysine, (3) rat tail collagen type 
I, ( 4) mouse collagen IV and (5) mouse laminin. Cells trypsinized following explant removal 
were seeded into these six well plates and incubated in growth medium for three days. After 
three days the cells were fixed and stained with 1.2% aqueous crystal violet solution as 
described in Chapter 2 and this Appendix. Density of cell populations were evaluated by light 
microscopy for cell adherence and general morphology. 
The Vitrogen I 00 worked consistently well . The fibroblasts adhered well and readily 
formed a monolayer. The results with the other commercial products varied. Attachment 
with the mouse laminin was poor. Fair attachment was noted with the rat tail collagen and the 
mouse collagen. Attachment was good with the poly-D-lysine. The human fibronectin 
resulted in the best cell viability and anchorage of the five commercially coated plates. In all 
plates but the human fibronectin and poly-D-lysine, the cell morphology was unusual. This 
may have been a sign of an adverse reaction to the attachment factor. Based on these 
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observations, it was concluded that continued use of the Vitrogen 100 was the best choice 
based on the flexibility of coating plates and flasks individually as needed rather than 
purchasing pre-coated plates. 
Tendon harvesting and cell culture 
Equine limbs were prepared aseptically. The hair was clipped circumferentially from 
the mid-carpal region to the pastern of both forel imbs and the excess loose hair was removed 
with the vacuum. A latex exam glove was placed over the hooves and the legs were 
suspended from an IV pole to allow circumferential aseptic preparation of the clipped area. 
Each metacarpal region was scrubbed for five minutes in a standard manner alternating 
between chlorhexidine and alcohol 
The skin over the palmar metacarpal region was incised aseptically and dissected back 
using a number # I 0 scalpel blade. Once the paratenon was exposed, the process was repeated 
on the opposite forelimb. The mid-metacarpal region of the superficial digital flexor (SDF) 
tendon was dissected free from the deep digital flexor tendon and was transected proximally 
and distally using a #20 scalpel blade. Following transection, the tendon was immediately 
placed in sterile HBSS in a sterile specimen container, sealed and transported to the laboratory 
for further processing. 
The tissue explants were prepared in the laminar flow hood. The tendon segments 
were removed one at a time from the HBSS and rinsed in PBS to remove adherent red blood 
cells. They were then immersed in 0.2% sodium hypochlorite for five seconds to disinfect the 
surface and rinsed a second time in PBS. The epitenon was removed from all four sides of 
each tendon segment using a sharp flame sterilized razor blade. The central core region was 
then cut sequentially into longitudinal strips of tendon 2-3 mm in width. Cut strips were 
stored in culture medium in a separate petri dish to avoid desiccation. The strips were minced 
into 1-2 mm3 tissue fragments and stored in culture medium. 
The tissue fragments were removed five to six at a time and briefly set on a piece of 
sterile filter paper to absorb excess moisture and increase adherence to the flask. Tissue 
fragments were placed one at a time 5-6 mm apart into 25 cm2 flasks using a flame sterilized 
metal spatula. A total of 30-40 tissue fragments were placed in each flask. Approximately 20 
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flasks were set per horse based on the number of cells required for each experiment. Set up of 
24 well plates was performed similarly with one tissue fragment centered in each well. 
When the medium was changed, approximately 60% of the total volume of medium 
was exchanged. New medium was added gently to the side of the flask or the well so as not 
to disrupt the tissue fragments or cells. Special care was taken not to disturb the tenuous 
attachment of the tissue fragments. On day 14 the tissue fragments were removed without 
disrupting the cells using a rubber cell scraper, removed using a pipette and discarded. The 
cells were trypsinized. 
Trypsinization of equine tendon fibroblasts 
The standard laboratory trypsinization protocol for fibroblasts was modified in an 
effort to maximize cell detachment and minimize cell trauma. A number of alternative 
protocols were tested and the modification described produced the best results. The original 
protocol is described for completeness. 
The flask surfaces, including the top, were rinsed gently using 2 ml of porcine 
pancreatic trypsin with ethylenediaminetetraacetate (EDTA) in saline A (ATV). The ATV 
was removed immediately and a fresh 2 ml of ATV was added to cover the entire bottom 
surface of the flask. The flask was capped and placed on a 3 7° C heating block and gently 
swirled periodically for three to five minutes until pin-point holes could be seen in the halos of 
cells. The flask was rapped against the palm of the hand to loosen the cells. Ideally, the cells 
would have been loose but not detached at this stage. The ATV was to be removed and 5 ml 
of growth media added to the 25 cm2 flask. The media would be pipetted up and down 
several times gently to break up the clumps of cells and transferred to clean labeled 25 cm2 
flasks and reincubated at 3 7° C and 5% C02. 
The standard trypsinization protocol as described above was apparently too strong for 
the equine fibroblasts. The cells were readily released from the flask and were floating free in 
the trypsin. Removal of the trypsin would have also removed the cells. As a result, the 
protocol was modified to retrieve the cells. The cells and trypsin were pipetted into a 6 ml 
snap cap tube and centrifuged for three minutes at 1000 RPM to form a cell pellet. The 
excess trypsin was removed leaving the cell pellet. Growth medium was added to the tube 
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and gently pipetted three to four times to break up the cell clumps. The media and cells were 
added to clean 25 cm2 flasks and were reincubated. 
The final modification that was utilized successfully throughout the later studies and 
worked well. The growth medium and tissue fragments were removed. The flask was rinsed 
with 2 ml ATV and this ATV was discarded. A fresh 2 ml of ATV was added and the flask 
was placed on the 3 7° C heating block for 3 0-60 seconds. The A TV was removed and the 
"dry" flasks were placed on the heating block for another two to four minutes. The flasks 
were rapped occasionally in the palm of the hand and the progress of the trypsinization was 
reassessed at 30-60 second intervals. When the cells were loose, 2 ml of growth medium was 
added per flask and pipette up and down two to three times. The cells were then combined in 
one of the two flasks trypsinized at the same time and stored in the incubator temporarily. 
When all of the flasks had been trypsinized, the cells were swirled, combined and distributed 
to the necessary plasticware for monolayer seeding. 
Electron and light microscopy 
Cells that were to be fixed in a monolayer were prepared in a similar fashion to that 
described in Chapter 2. Rather than scraping the cells, the glutaraldehyde was removed and 
the bottom of the well was punched out using a # 10 cork borer from the outside. The disks 
were placed in a scintillation vial in fresh glutaraldehyde and stored in the refrigerator 
overnight. Those monolayers that were seeded on well inserts were fixed in a manner similar 
to that just described for the wells. The insert membranes were removed using scissors in 
place of the cork borer. These techniques were less than ideal for viewing the cells under EM 
due to the paucity of cells spread out over a large area and difficulties in processing the plastic 
discs for EM. The pellet method is preferable. 
Crystal violet staining for light microscopy was performed as described in Chapter 2. 
The staining process itself with the filtered crystal violet was performed for 15 minutes. 
Gamori's trichrome stain was used to specifically stain for collagen. The monolayer of cells 
was fixed by covering with 56° C preheated Bouin's solution for 30 minutes. The excess 
Bouin's was discarded and the monolayers were cooled and washed under running tap water 
until the yellow color disappeared. One rinse was performed with distilled water. The 
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monolayers were covered with Weigert's iron hematoxylin solution for ten minutes after which 
the excess Weigert's solution was discarded. A two minute rinse under running tap water was 
followed by a rinse with distilled water. Finally, the monolayer was covered with Gamori's 
trichrome stain for 15 minutes. The excess trichrome was discarded and the monolayer was 
covered with 0 .5% glacial acetic acid for one minute. The monolayers were allowed to dry. 
The colors in the stain and the structures they represent are displayed in Table A.2 . 
Table A.2. Key for Gamori ' s trichrome stain. 
Structure stained Color 
Muscle fibers Red 
Collagen Blue 
Nuclei Blue to ink 
T he results of the trichrome stain were disappointing. In the areas of dense cell 
populations, there were large accumulations of blue stain. It was difficult to determine 
whether these were areas of abundant collagen deposition or whether the stain accumulation 
was artifact from adherence to the cells themselves. The coloring may well have been true 
collagen deposition, but the final product was not useful for photography or measurement. 
Proteoglycan staining 
The presence of proteoglycan in the guanidine extraction solution and subsequently on 
the filter paper fo ll owing precipitation was tested with several different stains. 
Thymol/napthol (TIN) stain was made using 0.5 g thymol, 0.5 g napthol, 95 ml 95% ethanol 
and 5 ml concentrated sulfuric acid . Coumassie brilliant blue ( 1 %) (CBB) was premade as a 
stock solution. Toluidine blue (TB) was made using 100 ml O. IN acetic acid (94.3 ml dH20 
plus 5.7 ml glacial acetic acid ( 17 4N) with 0.2% toluidine blue. 
The filter paper was spotted with two separate spots. Both Whatman 3MM and CF/ A 
filter paper was used. One spot each of 10 µI and lµ I of guanidine extraction solution was 
spotted on the paper. The spots were allowed to dry and the proteoglycan was precipitated 
using CPC and allowed to dry again. The filter paper was dipped in the stain five times fo r a 
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total of about five seconds. The CBB and TB were rinsed with dH20 from the squirt bottle 
and destained in acetic acid for I 0-15 minutes. The TIN strips were placed on foil and placed 
in the 120° C oven for ten minutes. All strips confirmed the presence of proteoglycan on the 
filter paper, validating the guanidine extraction and CPC precipitation protocol. 
Cell labeline with Na/ 5S0 4 
Ideally the cells were labeled during the log phase of growth when they had created 
approximately 80% of a solid monolayer. The Na/ 5S04 was ordered in 2 .0 mCi doses in a 2 
µ l volume. Following delivery from Environmental Health and Safety, the manufacturer's 
reference date was recorded on a card in Room A and the Na2
35S04 was stored in the glass 
cabinet in the same room for future use. Prior to the first use, 198 µ l of sterile distilled water 
was added to the isotope vial to achieve a concentration of 10 µCi/ µ I. At this dilution, 4 µl 
was used per milliliter of medium to achieve a final concentration of 40µCi/ml. Whenever 
working with the isotope standard radiation safety protocols were observed. 
Scintillation counting 
Proteoglycan content was determined using a liquid scintillation counter. 
Background counts were recorded using a glass scintillation vial containing scintillation fluid 
and a plain piece of filter paper. Counter efficiency was estimated using 100 µ1 of 
C 14-leucine spotted onto a piece of filter paper and placed in a glass counting vial with 
scintillation fluid . The background counts were performed on the same channel as the control 
and treatment samples. 
Dilution of PSGAG 
The intra-articular form of Adequan (IA) was utilized as PSGAG for all treatments. 
The stock solution of250 mg/ml was diluted I : 10 with sterile distilled water (100 µ1 PSGAG 
added to 900 µ 1 dH20) in a microcentrifuge tube. This created a concentration of 25 µgl µ I. A 
second I : l 0 dilution was performed to achieve a concentration of 2 . 5 µ gl µ I. Appropriate 
volumes of these stock solutions were added to the medium to achieve the desired 
concentrations. 
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Materials 
All chemicals and biochemicals were obtained from Sigma Chemical Company (St. 
Louis) with the following exceptions: DMEM, IL packets of powder (GIBCO Laboratories, 
Grand Island, NY), FBS, premium grade (GIBCO Laboratories, Grand Island, NY and 
Summit Biotechnology, Fort Collins, CO), rhIGF-1 (Sigma Chemical Company, St. Louis, 
MO and Fisher Scientific, Itasca, NY), Vitrogen 100 (Flow Laboratories, McLean, VA), 
N~S04 (ICN Pharmaceuticals, Irvine, CA), 14C-leucine (ICN Pharmaceuticals, Irvine, CA), 
PSGAG (Adequan, Luitpold Pharmaceuticals, Shirley, NY), commercially coated six well 
plates (Fisher Scientific, Itasca, NY). 
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APPE DJX B. ELECTRON MICROGRAPHS 
(a) 
(b) 
Figure B. l . Transmission e lectron micrographs of equine tendon fi broblasts. (a) 
approximately 23 X 103x and (b) approximately 33 X I 03x. Note the extracellular 
matri x products (co llagen and proteoglycan) accumulated outside the cells (A). 
(a) 
(b) 
Figure B .2. 
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T ransmission electron micrographs of equine tendon fibroblasts. (a) 
approx imate ly 23 X I 03x and (b) approximately 33 X I 03x. o te the abundant 
ro ugh endoplasmic reticulum with dilated cisternae containing granular materia l 
(arrow head) and ex tracellular matrix between the cells (A). 
(a) 
(b) 
Figure 8 .3. 
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.. 
Transmission electron micrographs of equine tendon fibroblasts. (a) 
approx imately 8 X I 03x and (b) approx imately 13 X I 03x. Note the abundant 
rough endoplasmic reticulum with dilated cisternae containing granular material 
(arrow head) and ex tracellular matrix between the cells (A). 
(a) 
(b) 
Figure B.4. 
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Transmission e lectron micrographs o f equine tendon fibroblasts. (a) 
approx imate ly 8 X I 03x and (b) approx imately 23 X I 03x. ote the abundant 
rough endoplasmic reti culum with di lated cistemae containing granular material 
(arrow head) and ex tracellular matrix between the cells (A). 
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